ES2039239T3 - Vacuna contra el virus varicela-zoster. - Google Patents

Vacuna contra el virus varicela-zoster.

Info

Publication number
ES2039239T3
ES2039239T3 ES87303561T ES87303561T ES2039239T3 ES 2039239 T3 ES2039239 T3 ES 2039239T3 ES 87303561 T ES87303561 T ES 87303561T ES 87303561 T ES87303561 T ES 87303561T ES 2039239 T3 ES2039239 T3 ES 2039239T3
Authority
ES
Spain
Prior art keywords
vaccine
glycoprotein
sequence
zoster
varicela
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87303561T
Other languages
English (en)
Inventor
Paul M Keller
Ronald W Ellis
Robert S Lowe
Mark W Riemen
Andrew J Davison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2039239T3 publication Critical patent/ES2039239T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE HA IDENTIFICADO POR ANALISIS DE LAS SECUENCIAS ADN UN GEN DE VIRUS DE VARICELLA-ZOSTER (VVZ) QUE CODIFICA PROTEINAS VIRICAS EN LA SUPERFICIE EXTERIOR INMUNOGENICA. LOS ANTICUERPOS DIRIGIDOS CONTRA PEPTIDOS FORMADOS A PARTIR DE LA SECUENCIA DE ADN PUEDEN REACCIONAR CON LA GLICOPROTEINA, QUE A SU VEZ ES REACTIVA CON ANTICUERPOS NEUTRALIZANTES. LA SECUENCIA AMINOTERMINAL DE LA GLICOPROTEINA ES IDENTICA A UNA PORCION DE LA SECUENCIA DE AMINOACIDOS FORMADOS A PARTIR DE LA SECUENCIA DE ADN. ESTA GLICOPROTEINA ES UTIL PARA LA PREPARACION DE UNA VACUNA CONTRA EL VIRUS VVZ.
ES87303561T 1986-05-02 1987-04-23 Vacuna contra el virus varicela-zoster. Expired - Lifetime ES2039239T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/859,159 US4952674A (en) 1986-05-02 1986-05-02 Vaccine against varicella-zoster virus

Publications (1)

Publication Number Publication Date
ES2039239T3 true ES2039239T3 (es) 1995-04-01

Family

ID=25330208

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87303561T Expired - Lifetime ES2039239T3 (es) 1986-05-02 1987-04-23 Vacuna contra el virus varicela-zoster.

Country Status (8)

Country Link
US (2) US4952674A (es)
EP (1) EP0244155B1 (es)
JP (1) JP2530847B2 (es)
AT (1) ATE73495T1 (es)
DE (1) DE3777233D1 (es)
DK (1) DK222587A (es)
ES (1) ES2039239T3 (es)
IE (1) IE59791B1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405867B1 (en) * 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
US5434074A (en) * 1991-07-05 1995-07-18 Gibson; D. Wade Cytomegalovirus proteinase
US6406902B1 (en) 1991-07-05 2002-06-18 Johns Hopkins University Herpes virus proteinase and methods of assaying
ES2165367T5 (es) 1992-07-17 2009-08-05 MERCK & CO., INC. Procedimiento para prevenir el herpes zoster o para aliviar la neuralgia post-herpetica relacionada con la varicela.
CA2177060A1 (en) * 1993-12-21 1995-06-29 Philip J. Provost Thermostable varicella zoster virus
AU2361495A (en) 1994-04-28 1995-11-29 Aviron A novel vzv gene, mutant vzv and immunogenic compositions
KR100374308B1 (ko) * 1995-07-27 2003-12-18 주식회사 엘지생명과학 재조합차이니스햄스터오바리세포로부터발현된수두바이러스의지피i당단백질의정제방법
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE69738597T2 (de) * 1996-02-09 2008-07-24 Glaxosmithkline Biologicals S.A. Vakzine gegen das varicella zostervirus produkt von gen 63
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
US5710248A (en) 1996-07-29 1998-01-20 University Of Iowa Research Foundation Peptide tag for immunodetection and immunopurification
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EP2670443A4 (en) * 2011-01-31 2015-10-14 Univ Pennsylvania NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USING SAME
JP2023516629A (ja) * 2020-02-28 2023-04-20 セルトリオン， インク． 水痘帯状疱疹ウイルス融合タンパク質およびこれを含む免疫原性組成物
CN114081943B (zh) * 2021-11-08 2024-04-02 中国医学科学院医学生物学研究所 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration

Also Published As

Publication number Publication date
JP2530847B2 (ja) 1996-09-04
EP0244155B1 (en) 1992-03-11
IE871169L (en) 1987-11-02
EP0244155A1 (en) 1987-11-04
DK222587A (da) 1987-11-03
US4952674A (en) 1990-08-28
US5306635A (en) 1994-04-26
IE59791B1 (en) 1994-04-06
DK222587D0 (da) 1987-05-01
JPS62285792A (ja) 1987-12-11
DE3777233D1 (de) 1992-04-16
ATE73495T1 (de) 1992-03-15

Similar Documents

Publication Publication Date Title
ES2039239T3 (es) Vacuna contra el virus varicela-zoster.
EA200100425A1 (ru) Новые способы терапевтической вакцинации
ES2059565T3 (es) Virus mva de la vacuna, recombinante.
ES2119776T3 (es) Proteina d- una proteina que une igd de haemophilus influenzae.
DK217288A (da) Dna, der indkoder t-celleoverfladeproteinet t4, og anvendelse af t4-fragmenter ved behandling af aids
ES2164070T3 (es) Inmunogenos quimericos.
DE3588022T3 (de) Pre-S genkodierte Hepatitis B Peptide und diese enthaltende Immunogene und Vakzine
DE3278344D1 (en) Stabilization of influenza virus vaccine
BR9708401A (pt) Vetores de vìrus de para-varìola
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
ES8801372A1 (es) Un metodo para preparar una vacuna contra el virus de la influenza equina.
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
MX9304765A (es) Vacuna de adenovirus recombinante.
AR036793A1 (es) Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
FI924222A (fi) Gp75 som ett tumoervaccin mot melanoma
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).
AR241713A1 (es) Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ES2125236T3 (es) Mejoras relativas a la deteccion de virus.
CO5300406A1 (es) Vacuna
ES2077017T3 (es) Vacuna contra el virus de la bronquitis infecciosa.
PT91316A (pt) Processo para a preparacao de vectores recombinantes e de particulas hbsag recombinantes hibridas tendo as caracteristicas morfologicas do antigenio hbsag contendo uma sequencia imunogenica que induz anticorpos neutralizantes dirigidos contra hiv ou susceptivel de ser reconhecida por tais anticorpos
CU22666A1 (es) Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 244155

Country of ref document: ES